Which startups have raised the most funding in the MedTech market?
A constantly refreshed list of the top startups in the MedTech market, ranked by cumulative funding raised

In our updated market reports, you will find everything you need
The MedTech market has become one of the largest funding arenas in healthcare, with capital flowing into diagnostics, surgical robotics, neurotechnology, wearables, and cardiovascular devices.
We update this list every month, so the ranking reflects the latest public fundraising data we can verify.
The goal is simple, help founders, investors, and operators quickly see which MedTech startups have raised the most money and where funding is concentrating.
A quick summary table
| Metric | Value |
|---|---|
| Most funded startup | Grail, $1.7B raised |
| Second most funded startup | Freenome, $1.3B raised |
| Largest funding round | BVI Medical, $1.0B strategic capital raise |
| Median funding | $199.5M |
| Share of funding captured by the top 10 | 35.4% |
| Median time since last round | About 18 months |
| Startups that raised funding in the last 12 months | 30 startups |
| Total MedTech startup funding tracked | $30.3B |
| MedTech startups still active | 78 startups |
| MedTech IPO or acquired outcomes | 22 startups |
Top startups in the MedTech market ranked by total funding raised
Here is an updated table that ranks the top startups in the MedTech market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Grail | Multi-cancer blood testing | $1.7B | 4 | May 2020 | $390M | Series D | PSP Investments, CPP Investments, Illumina | IPO | Full |
| 2 | Freenome | Early cancer blood tests | $1.3B | 7 | February 2024 | $254M | Equity financing | Roche, a16z, Quest Diagnostics | Active | Full |
| 3 | Neuralink | Implantable brain-computer interfaces | $1.3B | 5 | June 2025 | $650M | Series E | ARK Invest, Founders Fund, Sequoia Capital | Active | Strong |
| 4 | Oura | Smart ring health tracking | $1.3B | 6 | October 2025 | $900M | Series E | Fidelity, ICONIQ, Whale Rock | Active | Strong |
| 5 | CMR Surgical | Surgical robotics platform | $1.1B | 5 | September 2023 | $165M | Series D / growth extension | Ally Bridge Group, SoftBank Vision Fund 2, Tencent | Active | Strong |
| 6 | Butterfly Network | Handheld ultrasound imaging | $1.0B | 4 | January 2025 | $76M | Public offering | Public-market investors, Fidelity, Glenview | IPO | Strong |
| 7 | BVI Medical | Ophthalmic surgical devices | $1.0B | 1 | March 2025 | $1.0B | Strategic capital raise | TPG, new investors | Acquired | Low |
| 8 | HeartFlow | AI coronary diagnostics | $855M | 6 | April 2023 | $215M | Series F | Bain Capital Life Sciences, Janus Henderson, Baillie Gifford | IPO | Partial |
| 9 | Saluda Medical | Closed-loop neuromodulation implants | $610M | 6 | December 2025 | $150M | IPO | Public investors, Wellington Management, Fidelity | IPO | Partial |
| 10 | Insightec | MR-guided focused ultrasound | $574M | 13 | June 2024 | $150M | Series G | Fidelity, Nexus Neurotech Ventures, Ally Bridge Group | Active | Partial |
| 11 | Beta Bionics | Automated bionic pancreas | $570M | 9 | January 2025 | $17M | PIPE | Wellington Management, Eventide, Marshall Wace | IPO | Strong |
| 12 | HistoSonics | Noninvasive tumor histotripsy platform | $553M | 7 | October 2025 | $250M | Growth equity | K5 Global, Bezos Expeditions, Wellington Management | Acquired | Strong |
| 13 | Impulse Dynamics | Heart failure implant therapy | $535M | 6 | December 2025 | $158M | Series F | Sands Capital, Braidwell, Redmile Group | Active | Partial |
| 14 | PROCEPT BioRobotics | Robotic BPH surgery system | $513M | 9 | September 2023 | $173M | Post-IPO Equity | Public investors, Perceptive Advisors, T. Rowe Price | IPO | Partial |
| 15 | CeQur | Wearable insulin delivery patch | $492M | 6 | June 2026 | $100M | Series E | Endeavour Vision, Credit Suisse Entrepreneur Capital, Tandem Diabetes Care | Active | Strong |
| 16 | Kardium | Atrial fibrillation ablation system | $471M | 6 | July 2025 | $250M | Late-stage financing | Janus Henderson Investors, Qatar Investment Authority, MMCAP | Active | Strong |
| 17 | Biofourmis | Virtual care digital medicine | $465M | 7 | August 2022 | $20M | Series D extension | Intel Capital, General Atlantic, CVS Health | Active | Strong |
| 18 | Cornerstone Robotics | Surgical robotics systems | $459M | 4 | November 2025 | $200M | Series D / new financing | HKIC, Qiming Venture Partners, Gaorong Capital | Active | Partial |
| 19 | RefleXion Medical | Biology-guided cancer radiotherapy | $449M | 6 | November 2023 | $105M | Equity Financing | The Rise Fund, Ally Bridge, Pfizer Ventures | Active | Strong |
| 20 | Exo | Handheld ultrasound platform | $410M | 5 | May 2025 | $100M | Venture / extension | Sands Capital, Bold Capital, Qubit Health Capital | Active | Partial |
| 21 | Kestra Medical Technologies | Wearable cardiac defibrillator platform | $398M | 2 | March 2025 | $202M | IPO | Public investors | IPO | Strong |
| 22 | Distalmotion | Dexter surgical robot | $390M | 6 | January 2026 | Undisclosed | Strategic equity investment | Johnson & Johnson Innovation – JJDC | Active | Partial |
| 23 | Cleerly | AI coronary imaging | $383M | 4 | December 2024 | $106M | Series C extension | Insight Partners, Battery Ventures, T. Rowe Price | Active | Partial |
| 24 | Aidoc | Clinical AI imaging platform | $370M | 7 | 2026 | $150M | Series E / Growth | Goldman Sachs Alternatives, General Catalyst, SoftBank | Active | Partial |
| 25 | NeuroPace | Responsive epilepsy neurostimulation | $366M | 9 | April 2021 | $102M | IPO | Accelmed, KCK Group, OrbiMed | IPO | Partial |
| 26 | JenaValve | Transcatheter aortic valve replacement | $364M | 13 | August 2022 | $100M | Series C | Bain Capital Life Sciences, Andera Partners, Valiance Advisors | Acquired | Partial |
| 27 | Imperative Care | Stroke thrombectomy devices | $345M | 4 | July 2021 | $260M | Series D | D1 Capital Partners, HealthCor, Innovatus Capital | Active | Partial |
| 28 | Synchron | Endovascular brain-computer interfaces | $345M | 4 | November 2025 | $200M | Series D | Double Point Ventures, ARCH Venture Partners, Khosla Ventures | Active | Strong |
| 29 | Neko Health | Preventive full-body health scans | $325M | 2 | January 2025 | $260M | Series B | Lightspeed Venture Partners, General Catalyst, Lakestar | Active | Full |
| 30 | Karius | Genomic infectious disease diagnostics | $315M | 5 | May 2024 | $100M | Series C | Khosla Ventures, 5AM Ventures, Gilde Healthcare | Active | Strong |
| 31 | Science Corp | Brain and retinal interfaces | $303M | 3 | March 2026 | $230M | Series C | Lightspeed Venture Partners, Khosla Ventures, Y Combinator | Active | Partial |
| 32 | Nalu Medical | Chronic pain neurostimulation | $289M | 4 | March 2024 | $85M | Series E | Novo Holdings, B Capital, Gilde Healthcare | Acquired | Strong |
| 33 | Caresyntax | Surgical intelligence software | $288M | 5 | August 2024 | $80M | Series C extension | Symbiotic Capital, BlackRock, Optum Ventures | Active | Partial |
| 34 | Mainstay Medical | Low-back pain neurostimulation | $284M | 5 | February 2024 | $125M | Public equity financing | Gilde Healthcare, Viking Global, Ally Bridge Group | IPO | Partial |
| 35 | Biolinq | Wearable metabolic biosensors | $280M | 5 | April 2025 | $100M | Series C | Alpha Wave Ventures, RiverVest, AXA IM Alts | Active | Strong |
| 36 | 4C Medical Technologies | Transcatheter heart valve therapies | $255M | 5 | March 2025 | $175M | Series D | Boston Scientific, MicroPort CardioFlow, Anges Québec | Active | Strong |
| 37 | PathAI | AI pathology diagnostics platform | $255M | 5 | May 2021 | $165M | Series C | D1 Capital, Kaiser Permanente, General Atlantic | Active | Strong |
| 38 | SetPoint Medical | Neuroimmune modulation for autoimmune disease | $250M | 4 | August 2025 | $115M | Series D | Elevage Medical Technologies, Ally Bridge Group, Abbott | Active | Partial |
| 39 | Viz.ai | AI care coordination platform | $250M | 5 | April 2022 | $100M | Series D | Tiger Global, Insight Partners, Scale Ventures | Active | Full |
| 40 | Paige | AI digital pathology software | $241M | 6 | January 2023 | $20M | Strategic equity | Microsoft | Acquired | Strong |
| 41 | Supira Medical | Percutaneous ventricular assist devices | $240M | 5 | March 2025 | $120M | Series E | Novo Holdings, Qatar Investment Authority, Cormorant Asset Management | Active | Full |
| 42 | VitalConnect | Wearable biosensor cardiac monitoring | $240M | 6 | February 2025 | $100M | Series G | Ally Bridge Group, EW Healthcare Partners, MVM Life Science Partners | Active | Partial |
| 43 | Orchestra BioMed | Cardiovascular therapy device developer | $220M | 5 | May 2026 | $20M | Public / corporate equity | Medtronic, Ligand | IPO | Partial |
| 44 | Medical Microinstruments | Robotic microsurgery platform | $220M | 4 | February 2024 | $110M | Series C | Fidelity, Deerfield, RA Capital | Active | Partial |
| 45 | Hyperfine | Portable MRI imaging system | $216M | 2 | December 2021 | $126M | PIPE / de-SPAC | HealthCor, Catalio, PIPE investors | IPO | Partial |
| 46 | Pulnovo Medical | Pulmonary hypertension device therapy | $215M | 4 | April 2026 | $100M | Strategic Financing | Medtronic, EQT, Qiming Venture Partners | Active | Strong |
| 47 | Blackrock Neurotech | Brain-computer interfaces | $210M | 2 | April 2024 | $200M | Strategic investment | Tether Evo, re.Mind Capital, Peter Thiel | Acquired | Full |
| 48 | TytoCare | Remote medical exam platform | $205M | 8 | August 2023 | $49M | Series E / Growth | Insight Partners, MemorialCare, HOOPP | Active | Strong |
| 49 | FIRE1 | Heart failure monitoring | $201M | 5 | January 2025 | $120M | Series D | Polaris Partners, Elevage Medical Technologies, Sands Capital | Active | Partial |
| 50 | Galvanize Therapeutics | Pulsed electric field therapies | $200M | 2 | September 2025 | $100M | Series C | Sofinnova Partners, Norwest Venture Partners, Janus Henderson | Active | Strong |
| 51 | CereVasc | Minimally invasive hydrocephalus device | $199M | 3 | June 2026 | $85M | Series C | Piper Sandler Merchant Banking, JJDC, Medtronic | Active | Full |
| 52 | restor3d | Personalized orthopedic implants | $197M | 4 | August 2025 | $104M | Series B | Partners Group, existing shareholders | Active | Partial |
| 53 | Carlsmed | Personalized spine surgery | $196M | 5 | July 2025 | $101M | IPO | B Capital, USVP, public investors | IPO | Strong |
| 54 | Element Science | Wearable defibrillator platform | $193M | 4 | March 2020 | $146M | Series C | Deerfield Healthcare, Qiming Venture Partners USA, Cormorant | Active | Partial |
| 55 | ForSight Robotics | Robotic eye surgery | $190M | 3 | June 2025 | $125M | Series B | Eclipse, Adani Group, Reiya Ventures | Active | Full |
| 56 | Vicarious Surgical | Single-port surgical robotics | $188M | 5 | October 2025 | $6M | Post-IPO Equity | Lake Street Capital Markets, BD, Khosla Ventures | IPO | Partial |
| 57 | OrganOx | Organ preservation perfusion systems | $187M | 9 | February 2025 | $142M | Equity financing | HealthQuest, BGF, Lauxera | Acquired | Partial |
| 58 | Ronovo Surgical | Modular surgical robotics platform | $186M | 6 | September 2025 | $67M | Series D | JJDC, Lilly Asia Ventures, INCE Capital | Active | Partial |
| 59 | SonoThera | Ultrasound-guided gene therapy delivery | $186M | 2 | June 2026 | $125M | Series B | Vida Ventures, CureDuchenne Ventures, ARCH Venture Partners | Active | Strong |
| 60 | Magenta Medical | Miniature heart pump | $183M | 5 | July 2024 | $105M | Series D | Novo Holdings, Viking Global, RA Capital | Active | Partial |
| 61 | MicroTransponder | Stroke recovery VNS therapy | $180M | 10 | March 2025 | $65M | Series F | USVP, Gilde Healthcare, Longitude Capital | Active | Partial |
| 62 | Cardiac Dimensions | Mitral repair implant | $165M | 5 | March 2025 | $53M | Series E | Ally Bridge Group, Lumira, Arboretum | Active | Partial |
| 63 | Precision Neuroscience | Minimally invasive brain implants | $155M | 3 | December 2024 | $102M | Series C | General Equity Holdings, B Capital, Duquesne Family Office | Active | Full |
| 64 | Apreo Health | Emphysema airway scaffold | $153M | 2 | August 2025 | $130M | Series B | Bain Capital Life Sciences, Norwest, F-Prime | Active | Partial |
| 65 | Noah Medical | Robotic bronchoscopy platform | $150M | 1 | April 2023 | $150M | Series B | SoftBank Vision Fund, Prosperity7, Tiger Global | Active | Full |
| 66 | AliveCor | Personal ECG monitoring | $149M | 6 | August 2022 | Undisclosed | Series F | GE HealthCare, Khosla Ventures, Qualcomm Ventures | Active | Partial |
| 67 | LightForce Orthodontics | Custom 3D-printed braces | $144M | 3 | August 2023 | $80M | Series D | Ally Bridge Group, Transformation Capital, CareCapital | Active | Strong |
| 68 | Augmedics | AR spine surgery navigation | $142M | 4 | June 2023 | $83M | Series D | CPMG, Evidity Health Capital, H.I.G. Capital | Active | Full |
| 69 | Capstan Medical | Structural heart implants | $141M | 2 | December 2024 | $110M | Series C | Eclipse, Yu Galaxy, Intuitive | Active | Full |
| 70 | BioIntelliSense | Medical-grade wearable monitoring | $140M | 4 | December 2025 | $58M | Series C | Philips, Chimera, 7wireVentures | Active | Strong |
| 71 | Healthy.io | Smartphone kidney testing | $140M | 4 | May 2023 | $50M | Series D | Schusterman Family Investments, Aleph, existing shareholders | Active | Strong |
| 72 | Perspectum | AI medical imaging diagnostics | $140M | 9 | March 2023 | $55M | Series C | Oppenheimer, HealthQuest, Blue Venture Fund | Active | Partial |
| 73 | CardioFocus | Cardiac ablation systems | $138M | 4 | February 2023 | $32M | Series E | SV Health Investors, Kennedy Lewis, institutional syndicate | Active | Low |
| 74 | Eko Health | AI digital stethoscopes | $131M | 4 | June 2024 | $41M | Series D | ARTIS Ventures, Highland Capital Partners, NTTVC | Active | Partial |
| 75 | Neuspera Medical | Miniaturized neurostimulation implants | $125M | 5 | July 2024 | $23M | Series D | Vertex Ventures HC, Treo Ventures, Olympus | Active | Strong |
| 76 | Sight Diagnostics | AI blood diagnostics platform | $124M | 4 | August 2020 | $71M | Series D | Koch Disruptive Technologies, Longliv Ventures, OurCrowd | Active | Strong |
| 77 | Qure.ai | AI medical imaging diagnostics | $121M | 3 | September 2024 | $65M | Series D | Lightspeed, 360 ONE Asset, Merck GHI | Active | Strong |
| 78 | Proximie | Connected surgical platform | $119M | 3 | June 2022 | $80M | Series C | Advent Life Sciences, SoftBank Vision Fund 2, Mubadala | Active | Full |
| 79 | Momentis Surgical | Robotic surgical platform | $117M | 5 | November 2023 | $6M | Series D extension | Peregrine Ventures, Ceros, OurCrowd | Active | Partial |
| 80 | Think Surgical | Orthopedic surgical robotics systems | $105M | 2 | June 2023 | $5M | Strategic investment | KDB Investment Global Healthcare, David Dvorak | Active | Partial |
| 81 | CoMind | Non-invasive brain monitoring | $103M | 3 | October 2025 | $60M | Series A second close | Plural, Angelini Ventures, LocalGlobe | Active | Partial |
| 82 | Endotronix | Heart failure monitoring | $102M | 2 | October 2019 | $70M | Series D extension | LSP/EQT Life Sciences, BioVentures Investors, Lumira Ventures | Acquired | Partial |
| 83 | Ultromics | AI echocardiography heart diagnostics | $102M | 4 | July 2025 | $55M | Series C | L&G, Allegis Capital, Lightrock | Active | Strong |
| 84 | Amber Therapeutics | Neuromodulation for incontinence | $100M | 2 | June 2024 | $100M | Series A | NEA, F-Prime Capital, Lightstone Ventures | Active | Strong |
| 85 | RapidAI | Clinical AI imaging workflows | $100M | 2 | July 2023 | $75M | Series C | Vista Credit Partners, Lennertz & Co. | Active | Full |
| 86 | Notal Vision | Remote retinal disease monitoring | $89M | 3 | June 2021 | $60M | Series D | Soleus Capital, Ganot Capital, Elron | Active | Partial |
| 87 | Paradromics | Brain-computer interface implants | $89M | 12 | February 2025 | Undisclosed | Series A extension | Prime Movers Lab, Green Sands, Synergy Ventures | Active | Partial |
| 88 | Moon Surgical | Collaborative surgical robotics | $87M | 2 | May 2023 | $55M | Series B | Sofinnova Partners, NVentures, GT Healthcare | Active | Strong |
| 89 | SPR Therapeutics | Peripheral nerve stimulation pain relief | $87M | 3 | February 2024 | $25M | Series D-1 equity | Revelation Partners, RC Capital, Mutual Capital Partners | Active | Partial |
| 90 | Theranica | Wearable migraine neuromodulation device | $86M | 4 | August 2022 | $45M | Series C | New Rhein Healthcare Investors, aMoon, Lightspeed Venture Partners | Active | Strong |
| 91 | Scopio Labs | Digital microscopy and hematology AI | $73M | 3 | February 2022 | $50M | Series C | OurCrowd, Aurum Ventures, Ilex Medical | Active | Partial |
| 92 | FineHeart | Implantable heart pump | $73M | 4 | January 2026 | $41M | Series C | Groupe Pasteur Mutualité, Groupe Etchart, EIC Fund | Active | Strong |
| 93 | Adagio Medical | Cardiac cryoablation devices | $72M | 6 | October 2025 | $19M | PIPE | ArrowMark, RA Capital, Perceptive Advisors | IPO | Partial |
| 94 | WISE | Implantable neurotechnology electrodes | $62M | 4 | June 2026 | $34M | Series D | ENEA Tech and Biomedical, CDP Venture Capital, Principia SGR | Active | Strong |
| 95 | Quibim | AI imaging biomarkers | $60M | 4 | January 2025 | $50M | Series A | Asabys Partners, Buenavista, Amadeus Capital | Active | Partial |
| 96 | Materna Medical | Women’s pelvic health devices | $57M | 5 | July 2026 | $5M | Series B3 | InnovaHealth Partners, Wavemaker360 Health, Band of Angels | Active | Partial |
| 97 | CroíValve | Transcatheter tricuspid valve repair | $45M | 3 | June 2026 | $20M | Series B expansion | BGF, EIC Fund, MedTech Syndicate | Active | Strong |
| 98 | CardioMech | Mitral valve repair | $42M | 3 | January 2024 | $13M | Series B-style equity | Hadean Ventures, Investinor, strategic investor | Active | Partial |
| 99 | LensGen | Fluid-optic intraocular lens | $41M | 4 | March 2023 | $6M | Bridge financing | HOYA Group, Relativity Healthcare Partners, ExSight Ventures | Active | Strong |
| 100 | C2N Diagnostics | Alzheimer’s blood diagnostics | $35M | 2 | March 2025 | $10M | Strategic Equity | Samsung Venture Investment, Samsung Biologics, Samsung C&T | Active | Low |
Key funding trends in the MedTech market
Insights
- The top 10 MedTech startups raised about $10.7B, or 35.4% of the total funding tracked, which shows how strongly capital concentrates around category leaders.
- Cancer blood testing is one of the clearest mega-funding themes in MedTech, with Grail and Freenome alone raising about $3.0B across multi-cancer and early cancer diagnostics.
- Neurotechnology has moved beyond niche device funding, with Neuralink, Synchron, Blackrock Neurotech, Precision Neuroscience, and WISE raising about $2.0B combined.
- Surgical robotics remains extremely capital intensive, with CMR Surgical, Cornerstone Robotics, ForSight Robotics, Ronovo Surgical, Moon Surgical, and Vicarious Surgical representing a large funding cluster.
- Wearable and remote-monitoring MedTech companies are scaling across consumer and clinical markets, led by Oura, Butterfly Network, BioIntelliSense, Healthy.io, Sight Diagnostics, and VitalConnect.
- Cardiovascular devices remain a durable investor category, with strong funding across ablation, heart failure monitoring, valve repair, ventricular support, and coronary diagnostics.
- Several MedTech startups raised very large totals across only a few rounds, including Neko Health, Noah Medical, Blackrock Neurotech, Galvanize Therapeutics, and Apreo Health.
- AI diagnostics is no longer a small software subcategory, with HeartFlow, Cleerly, Aidoc, PathAI, Viz.ai, Qure.ai, and Ultromics all crossing meaningful funding thresholds.
A few word about our methodology
As you can see, we built a database that ranks startups in the MedTech market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.
Related blog posts
- What are the key fundraising trends in the MedTech market?
- The highest-valued startups in the MedTech market
- What does funding activity look like in the MedTech market?
- A complete overview of funding deals in the MedTech market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.